Oncology providers’ perspectives on endocrine therapy prescribing and management

References

• CarlsonRWHudisCAPritchardKINational Comprehensive Cancer NetworkBreast Cancer Clinical Practice Guidelines in OncologyAmerican Society of Clinical Oncology Technology Assessment on the Use of Aromatase InhibitorsSt Gallen International Expert Consensus on the Primary Therapy of Early Breast CancerAdjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendationsJ Natl Compr Canc Netw200641097197917112447
   PubMedGoogle Scholar
• MurphyCCBartholomewLKCarpentierMYBluethmannSMVernonSWAdherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic reviewBreast Cancer Res Treat2012134245947810.1007/s10549-012-2114-5 Epub201261222689091
   PubMed Web of Science ®Google Scholar
• CluzeCReyDHuiartLAdjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over timeAnn Oncol20122388289021788360
   PubMed Web of Science ®Google Scholar
• DentSFGaspoRKissnerMPritchardKIAromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerBreast Cancer Res Treat201112629531021249443
   PubMed Web of Science ®Google Scholar
• OberguggenbergerAHubalekMSztankayMIs the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)Breast Cancer Res Treat201112855356121311968
   PubMed Web of Science ®Google Scholar
• BhosleMJOutcomes Associated with Adjuvant Hormonal Therapy: Are There Any Differences Between Black and White Women with Primary Breast Cancer?Ann ArborProQuest Information & Learning2008
   Google Scholar
• FilesJAKoMGPruthiSManaging aromatase inhibitors in breast cancer survivors: not just for oncologistsMayo Clin Proc20108556056620511486
   PubMed Web of Science ®Google Scholar
• SmithSLWaiESAlexanderCSingh-CarlsonSCaring for survivors of breast cancer: perspective of the primary care physicianCurr Oncol201118e218e22621980253
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNPritchardKIExtending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsN Engl J Med201665 Epub ahead of print
   Web of Science ®Google Scholar
• WardJHDuration of adjuvant endocrine therapy of breast cancer: how much is enough?Curr Opin Obstet Gynecol201022515519952743
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyBreast Cancer OverviewAmerican Cancer Society Web site Last Revised January 15, 2016. Available from: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-hormone-therapyAccessed February 2, 2016
   Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group; Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• KahnKLSchneiderECMalinJLAdamsJLEpsteinAMPatient centered experiences in breast cancer: predicting long-term adherence to tamoxifen useMed Care200745543143917446829
   PubMed Web of Science ®Google Scholar
• RobertsMCWheelerSBReeder-HayesKRacial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewAm J Public Health2015105Suppl 3e4e1510.2105/AJPH.2014.302490 Epub2015423
   Web of Science ®Google Scholar
• PellegriniISarradon-EckASoussanPBWomen’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of viewPsychooncology20101947247919507263
   PubMed Web of Science ®Google Scholar
• WheelerSBKohlerREReeder-HayesKEEndocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumorsJ Cancer Surviv20148460361010.1007/s11764-014-0365-3 Epub201452824866922
   PubMed Web of Science ®Google Scholar
• RileyGFWarrenJLHarlanLCBlackwellSAEndocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part DMedicare Medicaid Res Rev201114
   Google Scholar
• FreundKMBattagliaTACalhounENational Cancer Institute Patient Navigation Research Program: methods, protocol, and measuresCancer20081133391339918951521
   PubMed Web of Science ®Google Scholar
• KoNYDarnellJSCalhounECan patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research ProgramJ Clin Oncol2014322758276425071111
   PubMed Web of Science ®Google Scholar
• BurtonMCollinsKALiffordKJThe information and decision support needs of older women (>75 yrs) facing treatment choices for breast cancer: a qualitative studyPsychooncology20152487888425534045
   PubMed Web of Science ®Google Scholar
• LubberdingSvan Uden-KraanCFTe VeldeEACuijpersPLeemansCRVerdonck-de LeeuwIMImproving access to supportive cancer care through an eHealth application: a qualitative needs assessment among cancer survivorsJ Clin Nurs2015241367137925677218
   PubMed Web of Science ®Google Scholar
• CellaDFallowfieldLJRecognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Res Treat200810716718017876703
   PubMed Web of Science ®Google Scholar
• HarrowADrydenRMcCowanCA hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancerBMJ Open201446e005285
   PubMed Web of Science ®Google Scholar
• WheelerSRobertsMCBloomDUnderstanding barriers and facilitators to endocrine therapy use: a qualitative study of racially diverse breast cancer patients and providersPaper presented at: Academy Health, Annual Research MeetingJune 2014San Diego, CA
   Google Scholar